The top 600 biopharma firms added $487 billion in market capitalisation in 2020, according to the Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review report, published today. 2020 also saw an unprecedented amount of cash flow into the sector. Drug developers raised a record-breaking $12.7 billion via IPO. This was more than twice the total raised in 2019, and the average amount raised ($167 million) nearly doubled. Private companies also broke records, with an astonishing $20bn invested by venture financers, although the total number of financing rounds was lower than in prior years.
Read the full article: Evaluate Vantage 2020 Review: Biopharma IPOs and Venture Financing Break Records //
Source: https://www.businesswire.com/news/home/20210211005294/en/Evaluate-Vantage-2020-Review-Biopharma-IPOs-and-Venture-Financing-Break-Records-Global-Drug-Stocks-Add-Half-a-Trillion-Dollars-in-Market-Capitalization